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ABSTRACT The functions of parathyroid hormone-
related protein (PTHrP) on morphogenesis, cell prolif-
eration, apoptosis, and calcium homeostasis have been
attributed to its N terminus. Evidence suggests that
many of these effects are not mediated by the N
terminus but by the midregion, a nuclear localization
sequence (NLS), and C terminus of the protein. A
knock-in mouse lacking the midregion, NLS, and C
terminus of PTHrP (Pthrp/) was developed. Pthrp/
mice had craniofacial dysplasia, chondrodysplasia, and
kyphosis, with most mice dying by d 5 of age. In bone,
there were fewer chondrocytes and osteoblasts per
area, bone mass was decreased, and the marrow was
less cellular, with erythroid hypoplasia. Cellular prolif-
eration was impaired, and apoptosis was increased.
Runx2, Ocn, Sox9, Crtl1, -catenin, Runx1, ephrin B2,
cyclin D1, and Gata1 were underexpressed while P16/
Ink4a, P21, GSK-3, Il-6, Ffg3, and Ihh were overex-
pressed. Mammary gland development was aberrant,
and energy metabolism was deregulated. These results
establish that the midregion, NLS, and C terminus of
PTHrP are crucial for the commitment of osteogenic
and hematopoietic precursors to their lineages, and for
survival, and many of the effects of PTHrP on devel-
opment are not mediated by its N terminus. The
down-regulation of Runx1, Runx2, and Sox9 indicates
that PTHrP is a modulator of transcriptional activation
during stem cell commitment. Toribio, R. E., Brown,
H. A., Novince, C. M., Marlow, B. Hernon, K., Lanigan,
L. G., Hildreth III, B. E., Werbeck, J. L., Shu, S. T.,
Lorch, G., Carlton, M., Foley, J., Boyaka, P., McCauley,
L. K., Rosol, T. J. The midregion, nuclear localization
sequence, and C terminus of PTHrP regulate skeletal
development, hematopoiesis, and survival in mice.
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Parathyroid hormone-related protein (PTHrP),
first described as the humoral mediator of cancer-
associated hypercalcemia (1–3), is a pleiotropic factor
with multiple physiological functions, including regula-
tion of morphogenesis, cell proliferation and differen-
tiation, and transplacental calcium transport (4). The
biological functions of PTHrP have been attributed to
its N terminus [PTHrP-(1–34)], which binds to the
parathyroid hormone (PTH) receptor 1 (PTH1R) (2,
5). While PTH is an endocrine factor exclusively pro-
duced by the parathyroid glands to regulate calcium
and phosphorus homeostasis, PTHrP functions as an
autocrine, paracrine, and intracrine factor in fetal and
adult tissues (6). Mice with ablation of the Pthrp gene
(Pthrp/) are characterized by chondrodysplasia, ac-
celerated chondrocyte differentiation and endochon-
dral ossification, and lethality within minutes of birth,
demonstrating that PTHrP is critical for survival and
skeletal morphogenesis (7, 8). PTHrP is also essential
in integument biology; the lack of PTHrP or the
PTH1R results in failure of mammary gland develop-
ment (9–11).
Although the emphasis of most research has been on
PTHrP interacting with the PTH receptor, the onto-
genic relevance of other domains is intriguing. There is
evidence that many of the effects of PTHrP on cell
proliferation, apoptosis, and transepithelial calcium
transport are mediated by the midregion, a nuclear
localization sequence (NLS), and the C terminus. The
midregion of PTHrP increases transplacental calcium
transport (12, 13), and PTHrP-(67–86) and PTHrP-
(38–94) are the most active midregion fragments (12,
13). Cell culture studies indicate that PTHrP has a NLS
that inhibits apoptosis and promotes cell proliferation
(14, 15). PTHrP-(67–94) interacts with importin  and
GTP-Ran to promote its translocation into the nucleus
(16, 17). A nuclear targeting sequence that inhibits
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apoptosis exists at PTHrP-(87–107) (15, 18–20), and
PTHrP-(109–139) is involved in its nuclear export (21).
PTHrP also has been implicated in pancreatic -cell
function, where it increases insulin production (22).
Amino, midregion, and C-terminal fragments of PTHrP
have been measured in humans under physiological
and pathological conditions (23–25); however, their
roles are poorly understood. These findings suggest
that PTHrP must be produced in proximity to its target
cells; thus, it is primarily autocrine and paracrine in
nature. The significance of the putative NLS and C
terminus was recently demonstrated in mice expressing
PTHrP-(1–84), which showed growth retardation and
lethality (26).
In this study, we evaluated the in vivo relevance of the
midregion, NLS, and C terminus of PTHrP by generat-
ing knock-in mice expressing PTHrP-(1–66), thus lack-
ing these domains, but preserving the N-terminal func-
tions of PTHrP. Knock-in mice had abnormal skeletal
development, impaired hematopoiesis, aberrant mam-
mary gland development, dysregulated energy metabo-
lism, and early lethality, confirming the hypothesis that
many of the effects of PTHrP on development are not
mediated by its N terminus. Moreover, our study also
provides evidence that the midregion of PTHrP partic-
ipates in development because compared to mice ex-
pressing PTHrP-(1–84) (26), mice expressing PTHrP-
(1–66) have a more severe phenotype.
MATERIALS AND METHODS
Generation of Pthrp/ mice
This study was approved by The Ohio State University Insti-
tutional Animal Care and Use Committee. To generate the
Pthrp/ mice, exon 4 was replaced by an exon 4 lacking the
sequence encoding for PTHrP-(67–137). RNA splicing was
predicted with GenScan (http://genes.mit.edu/GENSCAN.
html). Deletion was carried out via PCR with Tgo polymerase
(Roche, Indianapolis, IN, USA) to leave blunt ends (see
Supplemental Data). The targeted 1.1-kb exon 4 was flanked
by a 5.5-kb intronic long arm at the 5 end, and a 1.1-kb
intronic short arm at the 3 end (Supplemental Fig. S1A). A
SpeI restriction site was introduced between exon 4 and the
long arm to facilitate Southern blotting. Fragments were
cloned into pPNT to generate the final construct (pPNT-
PTHrP/). The construct was linearized with NotI, and 10 g
of DNA was electroporated into SV129/SvEv ES cells. Clones
were selected with G418, screened for homologous recombi-
nation by PCR, confirmed by Southern blot analysis, and
injected into E4.0 C57BL/6 blastocysts. Male chimeras were
bred to C57BL/6 females, and offsprings were selected on the
basis of agouti coat color, PCR, and Southern blot analysis.
Mice with homologous recombination were bred to C57BL/6
EIIa-Cre mice to excise the Neor cassette and generate the
breeding line (Pthrp/).
For Southern blot analysis, genomic DNA was digested with
SpeI, fractionated in a 0.5% agarose gel, transferred onto
nylon membranes, and hybridized with a 700-bp DNA probe.
This resulted in an 8.4-kb fragment in wild type and 7.0- and
8.4-kb fragments in recombinants. For the 3 end, DNA was
digested with BamHI and screened with a 1-kb DNA probe,
resulting in 7.5 kb for wild-type and 7.5 and 9.5 kb (Neor
cassette) fragments for recombinants (Supplemental Fig.
S1A). Sex was determined by PCR of the Sry gene. Primers
used in this study are listed in Supplemental Table S1.
Microcomputed tomography (micro-CT) and bone
morphometry
Whole pups and skull and long bone specimens were evalu-
ated with a high-resolution micro-CT system (Siemens, Nash-
ville, TN, USA). Images were reconstructed with IRW (Sie-
mens) and analyzed with bone morphometry software (Ratoc
System Engineering, Tokyo, Japan). Settings used were as
follows: pups 20 40, 400 projections, bin of 2, exposure
575 ms, energy  80 kV, current  500 mA, and 34.7-m
isotropic voxel size; head  33  9, 400 projections, bin of 1,
exposure  340 ms, energy  80 kV, current  500 mA, and
12.00-m voxel size; bone specimens  12  17, 380 projec-
tions, bin of 1, exposure  2175 ms, energy  70 kV,
current  100 mA, and 10.00-m isotropic voxel size. Vari-
ables analyzed included bone volume/total volume (BV/TV),
bone surface area/bone volume (BS/BV), trabecular thick-
ness (Tb.Th), trabecular number (Tb.N), trabecular spacing
(Tb.Sp), cortical wall thickness (C.Th), and bone mineral
density (BMD). See Supplemental Data.
Skeletal double-staining
Pups were euthanized, eviscerated, skinned, and fixed in 95%
ethanol for 48 h. Placement in acetone for 48 h allowed
residual fat removal. Skeletons were double-stained at room
temperature with 0.015% w/v Alcian blue and 0.005% w/v
Alizarin red S in a 1:9 mixture of acetic acid and 70% ethanol
for 48 h. After staining, pups were washed twice with distilled
water and immersed in 1% KOH for 48 h to remove addi-
tional soft tissue. Skeletons were cleared in increasing con-
centrations of glycerol (from 20 to 100%) over a 2-wk period.
Hematology, blood chemistry, hormones, and bone markers
Total calcium concentrations were measured with a colori-
metric assay (BioAssay Systems, Hayward, CA, USA). Serum
triglycerides, phosphorus, glucose concentrations, and alka-
line phosphatase activity were analyzed with a biochemistry
analyzer (Roche Hitachi, Indianapolis, IN, USA). Hemo-
grams were performed manually in a veterinary hematology
laboratory. Mouse-specific enzyme immunoassays were used
to determine the serum concentrations of PTH (Alpco,
Salem, NH, USA), osteocalcin (Biomedical Technologies,
Stoughton, MA, USA), TRAP 5b (IDS, Scottsdale, AZ, USA),
and insulin (Alpco). Plasma PTHrP concentrations were
determined with a 2-site immunoradiometric assay (DSL,
Webster, TX, USA).
Histology and histomorphometry
Tissue specimens for histological evaluation were fixed in
10% buffered formalin at 4°C for 24 h, embedded in paraffin,
cut in 4-m sections, and stained with hematoxylin and eosin
(H&E). In addition, bone specimens were decalcified in 10%
EDTA (pH 7.4) at 4°C for 1–7 d. Fetal bone specimens were
not decalcified. For skin examination, embryonic day (E)18.5
fetuses and neonate skin were fixed in 10% cold buffered
formalin for 24 h, and subsequently in cold 70% ethanol.
Mammary tissue was assessed by serial sectioning. Images were
acquired with an automated microscopy system (Aperio Tech-
nologies, Vista, CA, USA) and quantification performed with
ImagePro Plus (Media Cybernetics, Bethesda, MD, USA). For
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TRAP staining, the leukocyte acid phosphatase kit (Sigma-
Aldrich, St. Louis, MO, USA) was used.
Immunohistochemistry and TUNEL staining
For PTHrP, a goat polyclonal anti-human PTHrP-(1–34)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at
1:100 dilution, and the secondary antibody was biotinylated
rabbit anti-goat IgG (Vector Laboratories, Burlingame, CA,
USA) at 1:200 dilution. For caspase-3, a rabbit polyclonal
anti-mouse antibody (Cell Signaling, Danvers, MA, USA) was
used at 1:200 dilution. For Ki-67, a rat monoclonal anti-mouse
antibody (Dako, Carpinteria, CA, USA) was used at 1:100
dilution. For von Willebrand factor, a rabbit polyclonal anti-
mouse antibody (Dako) was used at 1:1000 dilution. To assess
apoptosis via TUNEL, we used the Apoptag Plus Peroxidase
Kit (Millipore, Billerica, MA, USA) and the In Situ Cell Death
Detection Kit, POD (Roche).
Proliferation of primary chondrocytes and osteoblasts
Growth plates from newborn pups were harvested, rinsed with
PBS, minced, and digested at 37°C for 2 h with 1 mg/ml of
collagenase A (Roche) and 0.25% trypsin/EDTA (Invitrogen,
Carlsbad, CA, USA) in 	-minimum essential medium (	-
MEM) without FBS, at 60 rpm. Tissue was mixed by gently
pipetting 10 times. After 2 h, the remaining tissue was allowed
to sediment, and less-dense tissue was harvested. The cell
suspension was filtered through a 70-m cell strainer (BD
Biosciences, San Jose, CA, USA), rinsed with PBS, counted,
and plated at a density of 100,000 cells/well in 	-MEM, 10%
FBS, penicillin (100 U/ml), and streptomycin (100 g/ml).
Chondrocyte proliferation was assessed by plating 15,000 cells/
well in 24-well plates. Cells were counted in triplicate at 24, 48,
and 72 h. For osteoblasts, calvariae were dissected from 2-d-old
mice, isolated from periosteum, and subjected to sequential
digestions of 10, 20, and 30 min with 2 mg/ml of collagenase A
and 0.25% trypsin. Cells from the third digestion were har-
vested. Proliferation and viability was assessed with the MTT
assay (Promega, Madison, WI, USA). PTHrP-(1–141) was gener-
ated in LCC15-MB transfected cells with the human PTHrP-(1–
141) cDNA; PTHrP-(1–86) was commercially available (Abcam,
Cambridge, MA, USA); and PTHrP-(67–139) was chemically
synthesized (GenScript, Piscataway, NJ, USA).
Von Kossa staining
To assess in vitro mineralization, primary calvarial osteoblasts
were plated in 12-well plates at 13,500 cells/cm2. On reaching
confluency, cultures were treated with mineralization me-
dium (	-MEM, 10% FBS, penicillin, streptomycin, 50 g/ml
ascorbic acid and 10 mM -glycerophosphate) for 21 d.
Cultures were performed in triplicate, and medium was
changed every other day. At the end of the culture period,
cells were fixed with 95% EtOH and stained with 5% AgNO3
using the von Kossa method.
Osteoclastogenesis
Spleens were dissected from 2-d-old mice, and dissociated
using a 70-m cell strainer (BD Biosciences) and the plunger
of a 1-ml syringe. Mononuclear cells were isolated via Ficoll
(Sigma-Aldrich) gradient centrifugation. Cells were plated on
glass slides coated with apatite-collagen complexes in 24-well
plates at 9.5  104 cells/cm2. Cells were cultured in 	-MEM,
10% FBS, penicillin, and streptomycin. Osteoclastogenesis
was induced with 30 ng/ml of RANKL (R&D Systems, Min-
neapolis, MN, USA) and 50 ng/ml of M-CSF (R&D Systems).
Medium was changed every other day. On d 6, cells were fixed
in citrate-buffered acetone/formaldehyde for 1 min and
stained for TRAP activity (Sigma-Aldrich). Red-stained TRAP
multinucleated (3 nuclei/cell) cells were enumerated, and
results were expressed as number of osteoclasts per well.
Flow cytometry
Primary chondrocytes were cultured for 48 h and treated with
camptothecin (10 M) for 4 h. After treatment, cells were
rinsed with cold PBS, detached with 0.05% trypsin, centri-
fuged 5 min at 200 g in PBS, resuspended in annexin V
binding buffer, treated with FITC annexin V and propidium
iodide (Invitrogen) for 15 min, and submitted to flow cytom-
etry in a FACSCalibur system (BD Biosciences). The cell
population in the bone marrow and spleen was assessed using
the CD3 (PE), CD11b (FITC), CD11c (APC-Cy7), and B220
(PerCP-Cy5.5) cell markers. Cells were collected in RPMI with
5% FBS, segregated with a syringe plunger, washed in RPMI,
centrifuged at 200 g  5 min, and resuspended in FACS
buffer (PBS1% BSA0.01% sodium azide) to a density of
1  106/ml (100 l). Primary antibody (20 l) was added for
30 min at 4°C, cells were centrifuged in 500 l of FACS buffer,
resuspended in 100 l of FACS buffer with 20 l of secondary
antibody, and submitted to flow cytometry (1104 cells were
counted). Lin–Sca-1c-Kit cell population was assessed in
the bone marrow. Antibodies were purchased from BD Bio-
sciences (San Diego).
Quantitative real-time PCR
Total RNA was extracted with TRIzol reagent (Invitrogen) and
submitted to a second extraction step using RNA isolation
columns and DNase I (Stratagene, La Jolla, CA, USA). Comple-
mentary DNA (cDNA) was synthesized using Superscript reverse
transcriptase (Invitrogen) or the First Strand Kit (SABiosciences,
Frederick, MD, USA). Initial gene expression profiling was
carried out with mouse-specific osteogenic, stem cell, and apo-
ptosis PCR arrays (SABiosciences). Real-time PCR was per-
formed under standard methods, using SYBR Green mix and a
Lightcycler 480 (Roche). Gene expression was normalized by
the GeNorm geometric averaging (27) of multiple mouse house-
keeping genes (B2m, Hprt1, Ubc, Gapdh, Ppia). Cycling conditions
were 94°C, 15 min, followed by 40 cycles of 94°C, 15 s; 57°C, 20 s;
72°C, 10 s. Primers are listed in Supplemental Table S1.
Western blot analysis
Tissue was pulverized in liquid nitrogen and homogenized in
ice-cold lysis buffer (100 mM NaCl, 50 mM Tris HCl, 1 mM
EDTA, 1mM Na3VO4, 1 mM NaF, 1 mM PMSF, 10% Triton
X-100, and 5 g/ml each of leupeptin, aprotinin, and pep-
statin A). Protein lysates (30 g) were boiled at 100°C in water
for 5 min, separated on 4–20% SDS-PAGE gels for 2 h,
transferred onto PVDF membranes at 90 v for one 1 h,
blocked in 2% BSA  5% skim milk/PBS-0.1% Tween-20
(PBS-T) for 30 min at room temperature. Primary antibodies
were from Santa Cruz Biotechnology: PTHrP (sc-9680), Runx1
(sc-8563), Runx2 (sc-8566), Sox9 (sc-17340), Gata1 (sc-1234),
Pax5 (sc-1974), -catenin (sc-7199), Notch-1 (sc-6014), p16/
Ink4a (M-156), -actin (sc-1616); Abcam: Bmi-1 (ab38295);
BD Biosciences: caspase-3 (CPP32); Signalway Antibody
(Pearland, TX, USA): EphrinB2, GSK-3, AKT, mTOR; R&D
Systems: Wnt-5a; Cell Signaling: PARP-1 (9542); Thermo Fisher
(Fremont, CA, USA): Cyclin D1 (RB212P0), P63 (MS1084P0),
P21 (MS454P0). Secondary antibodies were from Santa Cruz
Biotechnology.
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Statistical analysis
Results are expressed as means 
 sd. All data were assessed
for normality by the Shapiro-Wilk method. Appropriate para-
metric and nonparametric testing was performed depending
on data distribution. Comparisons among groups were per-
formed with 1-way ANOVA or Kruskal-Wallis rank test de-
pending on data distribution. Comparison between 2 groups
was performed using t test or Mann-Whitney U statistic
depending on data normality. Survival analysis was carried out
with the Kaplan-Meier probability estimator. Significance was set
at P  0.05. Figures and graphics were generated with Photo-
shop CS3 (Adobe, San Jose, CA, USA), SigmaPlot 10.0 (Systat,
Chicago, IL, USA), and Prism 4.0 (GraphPad, La Jolla, CA,
USA), and statistical analysis with SigmaStat 3.5 (Systat).
RESULTS
Generation of mice lacking the midregion, NLS, and
C terminus of PTHrP
A knock-in mouse lacking the sequence encoding for
PTHrP–(67–137) (Pthrp/), which comprises the mi-
dregion, NLS, and C terminus was engineered (Supple-
mental Fig. S1A). The presence of the mRNA for
Pthrp/ in bone, skin, liver, kidney, lungs, and placenta
was verified by RT-PCR, and the reading frame was
confirmed by sequencing (Supplemental Fig. S1A).
The presence of PTHrP-(1–66) was demonstrated in
placental tissue by Western blotting, in respiratory
epithelia and skin by immunohistochemistry, and in
mouse embryonic fibroblasts (MEFs) by immunocyto-
chemistry (Supplemental Fig. S1A, B). PTHrP secretion
was confirmed by immunoassay in conditioned me-
dium from Pthrp/ MEFs and human embryonic kid-
ney-293 cells transfected with Pthrp/ and Pthrp/
cDNA (Supplemental Fig. S1C). Pups from the fifth
generation onward were used for quantitative analysis.
PTHrP-(67–137) is required for growth and survival
There was no difference in body weight between
Pthrp/ and control pups at birth. Unlike PTHrP-
knockout (Pthrp/) pups, which died at birth (7),
Pthrp/ pups lived up to 20 d, but their growth rate was
significantly stunted compared to controls (Pthrp/;
Pthrp/) (Fig. 1A; Supplemental Fig. S2A), and their
mortality rate was higher (Fig. 1B). There were no
differences in fetal and placental weight, litter size, or
male:female ratio (PCR to Sry gene), and Pthrp/ pups
represented 25% of the litter (Mendelian ratio).
Lack of PTHrP-(67–137) alters skeletal and dental
development
Newborn Pthrp/ pups had a domed head with fore-
shortening of the maxilla and tongue protrusion
Figure 1. Mice lacking PTHrP-(67–137) (/) have im-
paired growth rate, increased mortality, and gross morpho-
logical abnormalities. A) Growth rate in / mice was
significantly stunted when compared to control mice (/,
/), with no differences between / and / animals.
B) Cumulative mortality rate for / pups was 35% by d 2
and 95% by d 10. C) / mice had a chondrodysplastic phenotype that was present as early as d E18.5 of gestation (i, white
arrow), at birth (ii), but was clearly evident at d 3 postpartum (iii). Dwarfism and kyphosis were apparent in pups older than
3 d (iii–v). Craniofacial dysplasia with foreshortening was present as early as E18.5 (i, black arrow). D) Skeletal staining of
3-d-old / mice revealed less calvarial and rib mineralization (black arrows), and chondrodysplasia (white arrows).
E) Micro-CT images of 15-d-old mice confirmed cranial dysplasia, spherical skulls, rostrocaudal facial shortening, kyphosis,
and chondrodysplasia. F) Gross craniofacial morphology of 2- to 12-d-old / pups revealed a spherical skull with rostral
foreshortening, tongue protrusion (black arrows), and delayed dental eruption with malaligned incisors that had a chalky
discoloration (white arrow). G) On micro-CT, lateral, coronal, and rostral views showed morphological differences between
/ and control skulls (i–iv). There were differences in dental structure. Notice the proximity of the tympanic ring (white
arrow) to the third molar in the / skull (iii), confirming foreshortening of the maxillae and mandible.
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(craniofacial dysplasia), short limbs (hypomelia, chon-
drodysplasia), and a hunched back (kyphosis) (Fig.
1C–E). Chondrodysplasia was evident as early as E18.5
(Fig. 1C). The abnormal skull morphology was consis-
tent with aberrant patterning (Fig. 1D–F). Pthrp/ mice
had less appendicular bone and skull mineralization
(Fig. 1D; Supplemental Fig. S2B). Incisor eruption was
delayed in Pthrp/ mice (d 7 in controls vs. 9 in
Pthrp/), with incisor and molar malocclusion, mal-
alignment, and chalky discoloration, indicating altered
mineralization (Fig. 1F). These findings were in con-
trast with Pthrp/ and Pthrp mice rescued with the
procollagen II promoter that have failure in dental
eruption (7, 28). On the basis of similar defects in
humans lacking the PTH1R (10) and from the present
study, it suggests that dental eruption is primarily
mediated by the N terminus since tooth eruption
occurred in Pthrp/ animals, although it was aberrant.
To further study bone morphological and structural
differences we performed micro-CT. In the proximal
tibia, BV, Tb.Th, C.Th, and BMD were decreased
(Table 1). In the skull, ratios assessing geometry were
significantly different (Fig. 1G; Table 2; Supplemental
Fig. S1D; Supplemental Videos S1 and S2). To assess
microscopic features associated with the observed skel-
etal phenotype, we carried out bone histomorphometry
and found that Pthrp/ medullary cavities were redder
than normal, growth plates and chondrocyte zones
were shorter with chondrocyte disorientation and fewer
chondrocytes per column (Fig. 2A–J), less C.Th and
Tb.Th (Fig. 2H, I), decreased osteoblast numbers (Fig.
2K, L), and a higher number of TRAP cells (osteo-
clasts) (Fig. 2M, N). Pthrp/ mandibles were shorter,
with incisors rostrally displaced, reduced bone area,
and more TRAP cells (Fig. 2P, Q). Molars had altered
cytodifferentiation, with irregular and disorganized
odontoblasts and ameloblasts (Fig. 2P). The decreased
bone mineralization of Pthrp/ was contrary to that of
Pthrp/ mice, which had increased mineralization (7).
The bone phenotype in Pthrp/ mice supports the
hypothesis that the midregion, NLS, and C terminus of
PTHrP are critical in skeletogenesis.
Histologically, Pthrp/ mice had fewer chondrocytes
and osteoblasts per area (Fig. 2K, L), and less prolifer-
ation, based on Ki-67 immunostaining (not shown). In
vitro, we did not find differences in chondrocyte prolif-
eration and osteoclast differentiation, but there was less
proliferation in Pthrp/ osteoblasts (Fig. 2O). Plasma
osteocalcin concentrations were lower in mutants (Sup-
plemental Table S2). There was no evidence that
Pthrp/ osteoclasts had functional alterations as there
were no differences in serum TRAP 5b concentrations
(Supplemental Table S2).
Enteral feeding or exogenous PTHrP failed to rescue
the lethal fate of Pthrp/ mice
Oral gavaging of newborn pups with a milk replacer, or
daily subcutaneous injections with PTHrP-(1–86),
PTHrP-(1–141), and PTHrP-(67–139) (40 ng/g body
weight) failed to rescue the lethal phenotype of
Pthrp/ mice. Treatment of calvarial osteoblasts with
these PTHrP peptides (100 pM) increased their prolif-
eration rate, but to a lesser extent than wild-type
osteoblasts (Fig. 2O). Likewise, PTHrP peptides in-
creased their mineralization rate, but less in Pthrp/
than in wild-type osteoblasts (not shown). These results
indicate that the fate of several physiological processes
is determined early in development and that the effects
of PTHrP on cell proliferation are primarily intracrine.
Absence of PTHrP-(67–137) impairs hematopoiesis
A major and unexpected finding in the Pthrp/ bone
marrow was decreased cellularity and cellular prolif-
TABLE 1. Microtomographic bone morphometry of the proximal tibia
Genotype BV/TV (%)
BS/BV
(1/mm) Tb.Th (m)
Tb.N
(1/mm) Tb.Sp (m) C.Th (m)
BMD
(mg/cc) SW/SLa HW/HLa
/ 18.0 
 4.0* 115 
 25* 19.0 
 6.0* 8.8 
 1.8* 100.0 
 20.0* 60.0 
 10.0* 139 
 25* 0.85 
 0.05* 0.48 
 0.04*
/ 30.0 
 5.0 84.1 
 12 29.0 
 4.0 12.8 
 0.7 60.0 
 20.0 90.0 
 10.0 194 
 24 0.71 
 0.05 0.41 
 0.03
/ 32.0 
 2.0 86.2 
 15 28.0 
 4.0 13.8 
 0.8 50.0 
 20.0 100.0 
 20.0 201 
 28 0.73 
 .05 0.40 
 0.03
Morphometry at d 5 (n4). BV/TV, bone volume/total volume; BS/BV, bone surface area/bone volume; Tb.Th, trabecular thickness;
Tb.N, trabecular number; Tb.Sp, trabecular spacing; C.Th, cortical wall thickness; BMD, bone mineral density; SW/SL, scapular width (cranial
to caudal angles) to length ratio; HW/HL, humeral width (at the distal growth plate) to length ratio (Figure 2). aHigher number indicates
shorter bones. *P  0.05.
TABLE 2. Skull microtomography
Genotype OC/OIa CI/OIa OC/CIa IT/OIa IM/MOb CV/OI BMD (mg/cc)
/ 0.75 
 0.02* 0.88 
 0.04* 0.85 
 0.05 0.81 
 0.02* 0.43 
 0.03* 70° 
 15* 148 
 40*
/ 0.51 
 0.04 0.66 
 0.01 0.81 
 0.06 0.53 
 0.03 0.62 
 0.05 108° 
 12° 280 
 65
/ 0.50 
 0.03 0.66 
 0.02 0.82 
 0.06 0.52 
 0.04 0.63 
 0.06 112° 
 15° 275 
 58
Microtomography at d 5 (n4). OC/OI, occipital-coronal to occipital-incisor ratio; CI/OI, coronal-incisor to occipital incisor; OC/CI,
occipital-coronal to coronal-incisor; IT/OI, intertemporal (lateral to lateral) to occipital-incisor ratio; IM/MO, incisor-molar to molar-occipital;
CV/OI, cervicovertebral to occipital-incisor angle. aRatios closer to 1 indicate sphere-like shape. bLower numbers indicate shorter maxillae. *P
0.05.
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eration (Ki-67), erythroid hypoplasia, fewer
megakaryocytes/area, erythrocyte-filled sinusoids,
and fewer hematopoietic precursors (Lin–Sca-1c-
Kit) (Figs. 2A–C, H, I and 3A, B; Supplemental Fig.
S2C). This was correlated with reduced cellularity
and increased cell necrosis and apoptosis in the
thymus and spleen, reduced extramedullary hemato-
poiesis, and decreased white and red blood cell
numbers in peripheral blood (Supplemental Figs.
S2E and S3B, C; Supplemental Table S2). Platelet
count was lower in Pthrp/ mice but did not reach
statistical significance. There was no evidence of
altered bleeding in Pthrp/ mice. Although all geno-
types showed an increase in bone marrow cellularity
from birth until d 6, Pthrp/ marrow remained less
cellular (Fig. 3A, B; Supplemental Fig. S2C). The
myeloid:erythroid (M:E) ratio was higher in Pthrp/
compared to controls, with this difference becoming
less apparent by d 6 (Fig. 3B). Day 4 Pthrp/ bone
marrow and spleen had a lower number, but a higher
percentage of CD3, CD11b, and CD11c cells (Sup-
plemental Fig. S3A). The percentage of B220 cells
was lower in the Pthrp/ bone marrow but higher in
the Pthrp/ spleen. IL-6 mRNA was increased in the
bone marrow and calvaria of Pthrp/ mice (Fig. 3B).
IL-6 is a bone proresorptive cytokine that increases
osteoclastogenesis. The potential role of PTHrP in
hematopoiesis has not been documented before this
study.
PTHrP-(67–137) is a regulator of mammary gland
development
Since the absence of PTHrP or the PTH1R in mice and
humans results in failure of mammary gland develop-
ment (9, 10), we performed histological examination of
the ventral skin of E18.5 Pthrp/ fetuses and deter-
mined they lacked the thickened epidermal invagina-
tions of the nipple but had a rudimentary mammary
duct system (Fig. 3C). This confirms the N terminus of
PTHrP as a key regulator of mammary development but
also suggests that domains within PTHrP-(67–137)
modulate mammogenesis.
Figure 2. Lack of PTHrP-(67–137) is asso-
ciated with aberrant osteogenesis and
odontogenesis. A–C) Gross and micro-
scopic evaluation of the tibia revealed
shorter bone length and red blood cell
retention in mutant (/) mice. D–J) His-
tomorphometric analysis of / long
bones demonstrated shorter physeal and
growth plate length, with shorter reserve,
proliferative, and hypertrophic zones;
shorter primary spongiosa (F, G, J); lower
numbers of resting, proliferating, and
hypertrophic chondrocytes; chondrocyte disorientation; loss of columnar polarity (F, G); and thinner cortical bone (H, I).
The / bone marrow had decreased cellularity and lower numbers of hematopoietic precursors, and sinusoids were
dilated with red blood cells (H, I; Supplemental Fig. S2). K–N) Osteoblast numbers were lower (K, L), while TRAP cell
numbers were higher in the / primary spongiosa (M, N). O) In vitro, / calvarial osteoblast proliferation was lower from
d 1–7, but there was no difference in mineralization (von Kossa staining) and osteoclast differentiation (TRAP) among
genotypes. Treatment with PTHrP-(1–141), PTHrP-(1–86), or PTHrP-(67–139) enhanced proliferation but to a lesser level
than wild-type osteoblasts. P) Histology of incisors from 2- to 3-d-old mice / mandibles revealed flattened trabeculae,
altered cytodifferentiation, abnormal cuspal formation, and decreased bone area. Q) Higher numbers of TRAP cells.
Values are means 
 sd; n  6. *P  0.05; **P  0.01. View: 40.
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PTHrP-(67–137) deficiency affects other body
systems
Pthrp/ pups that lived past d 7 developed intention
tremors consistent with cerebellar dysfunction (Supple-
mental Video S3). A number of these pups had hydro-
cephalus and cerebellar herniation through the foramen
magnum (Fig. 3D), likely from cranial malformation.
These signs could have also resulted from a lack of
neuroprotection from PTHrP, as Pthrp/ brains are
more susceptible to neuroexcitation (29). Of interest,
there was more TUNEL labeling and less Ki-67 immu-
nostaining in Pthrp/ brains (Supplemental Fig. S2D,
E). No macroscopic or histological epidermal or dermal
abnormalities were seen in Pthrp/ E18.5 fetuses or
newborn pups; however, by d 3, generalized marked
seborrhea sicca developed (Fig. 3E). This clinical appear-
ance was evident histologically as epidermal and follicular
basket-weave to compact hyperkeratosis (Fig. 3F).
At birth, no gross differences in subcutaneous or vis-
ceral adipose tissue were found; however, by d 1, Pthrp/
pups had signs of decreased dietary intake or defective
energy metabolism, including adipose tissue and hepato-
cyte glycogen depletion (Fig. 3F, G; Supplemental Fig.
S3B), hypoglycemia, hypotriglyceridemia, and hypoinsu-
linemia (Supplemental Table S2). We further observed
that pancreatic islet cell numbers and insulin immuno-
staining were decreased (not shown), and serum insulin
concentrations were lower (Supplemental Table S2). Our
findings indicate that PTHrP participates in the energy
metabolism and are further supported by studies showing
that PTHrP regulates pancreatic -cell function (22, 30).
No differences in the parathyroid, pituitary, and adre-
nal glands were found. Because Pthrp/ E18.5 fetuses and
0- to 6-d-old pups had hypocalcemia, we measured serum
PTH and PTHrP concentrations, with no differences
found (Supplemental Table S2). We speculate that the
lack of midregion PTHrP, which has been implicated in
transepithelial calcium transport (12, 13) may be respon-
sible for hypocalcemia in Pthrp/ mice. There is limited
information on PTHrP and intestinal calcium absorption
(31); however, PTHrP concentrations are 1000-fold
higher in milk than in blood (32).
PTHrP-(67–137) is a regulator of programmed cell
death
Since it has been proposed that the NLS of PTHrP
reduces apoptosis (14, 15, 19), TUNEL labeling, caspase-3
immunostaining, and PARP-1 immunoblotting were per-
formed, and we found higher apoptotic rates in Pthrp/
chondrocytes, splenocytes, thymocytes, bone marrow, and
brain (Supplemental Figs. S2D, E and S3C). We also
determined by flow cytometry that camptothecin-treated
primary chondrocytes had higher apoptotic rates (Supple-
mental Fig. S3D). These findings support that PTHrP-
(67–137) has in vivo antiapoptotic functions.
Absence of PTHrP-(67–137) alters skeletal and
hematopoietic gene expression
The abnormal skeletal phenotype of Pthrp/ mice
prompted us to assess the mRNA expression of genes
involved in osteogenesis, chondrogenesis, and apopto-
sis in the tibial metaphysis and calvariae of 2-d-old mice
Figure 3. Absence of PTHrP-(67–137) impairs hematopoiesis, mammogenesis, brain function, and skin development.
A) Vascular channels of / of E18.5 fetuses and d 2–6 pups were dilated with erythrocytes, with this difference becoming less
evident by d 6. Inset: megakaryocyte (von Willebrand factor-immunopositive cell) numbers were decreased in / specimens.
B) Bone marrow of 2-d-old / pups was less cellular and had a higher myeloid: erythroid (M:E) ratio that was less pronounced
by d 6, lower numbers but a higher percentage of Lin Sca-1 c-Kit hematopoietic stem cells, and higher Il-6 mRNA
expression. C) Mammary gland histology revealed that / fetuses lacked the epidermal changes that characterize nipple
morphogenesis observed in control fetuses; however, mammary ducts were observed in / fetuses (black arrow; 100). D) A
number of / brains had cerebellar herniation (arrow) and hydrocephalus (asterisk), which likely was associated with the
intention tremors (Supplemental Video S3) observed in these mice (20). E, F) / pups older than 3 d of age had marked
seborrhea sicca (E), which histologically revealed epidermal and follicular basket-weave to compact hyperkeratosis (F). G) /
pups had subcutaneous and visceral adipose tissue depletion that was evident on histological examination (5-d-old mice). Values
are means 
 sd. *P  0.05.
1953PTHRP-KNOCK-IN MICE HAVE ABERRANT MORPHOGENESIS
using PCR arrays. The following genes were further
evaluated by quantitative real-time PCR: Ocn, Runx2,
Ihh, Sox9, Fgf1, Fgf3, tuftelin1, Itga3, -catenin, ephrinB2,
EphB4, Crtl1, PPAR, Bcl2, and P63. To address the
abnormal hematopoietic phenotype, selected hemato-
poietic genes (Runx1, Gata1, PU.1, C/EBP, and Pax5)
were evaluated in the bone marrow. In the Pthrp/
metaphysis Runx2, Ocn, Sox9, Crtl1, -catenin, EphrinB2,
and Bcl2 were underexpressed, while Ffg3, Ihh, Itga3,
and Il-6 were overexpressed (Fig. 4A). In the bone
marrow, Runx1, Gata1, PU.1, and Pax5 were underex-
pressed (Fig. 4A). In the calvariae, Ocn and Crtl1 were
underexpressed, while Fgf3, Ihh, Il-6, and P63 were
overexpressed (Supplemental Fig. S3E). There were no
differences in Pthrp, Pth1r, or PPAR mRNA expression
(Fig. 4A). The underexpression of Runx2, Runx1, Sox9,
EphrinB2, -catenin, Gata1, and Pax5 was supported by
less protein detection on Western blots of tibial protein
extracts (Fig. 4B). In addition, there was more GSK-3,
P16/Ink4a, and less -catenin protein in the Pthrp/
bone samples. The abnormal gene expression and
protein patterns in Pthrp/ mice were consistent with
the abnormal skeletogenesis, decreased hematopoiesis,
and increased apoptosis observed, supporting PTHrP
as an important factor in cell fate.
A model for the role of PTHrP-(67–137) in
skeletogenesis and hematopoiesis
On the basis of the findings presented in this study, we
propose that in the bone and bone marrow compart-
ments PTHrP-(67–137) is necessary for the commit-
ment of mesenchymal and hematopoietic precursors to
their respective mature lineages (Fig. 5). Specifically,
the decreased osteoblast and chondrocyte numbers
and low plasma osteocalcin concentrations, together
with the underexpression of Runx2, Sox9, EphrinB2,
Crtl1, -catenin, and cyclin D1, and overexpression of
GSK-3 and P16/Ink4a indicate that PTHrP-(67–137) is
a regulator of this step in cellular development (Fig.
5A). Likewise, the decreased numbers of hematopoietic
precursors (Lin–Sca-1c-Kit), bone marrow hypocel-
lularity, and decreased Runx1, Gata1, Pax5, and PU.1
mRNA expression in Pthrp/ mice suggest that PTHrP
is important in hematopoiesis (Fig. 5B). The dysregu-
lation of genes involved in apoptosis and aging (GSK-
3, P16/Ink4a, -catenin, P63, Bcl-2, mTOR) supports
PTHrP as a regulator of these processes (Fig. 5C).
DISCUSSION
The biological functions of PTHrP on morphogenesis
have been attributed to its N terminus (7). Previous
studies suggesting that PTHrP has other domains with
biological functions (12, 13, 15, 18, 20, 33) prompted
us to generate a knock-in mouse lacking the midregion,
NLS, and C terminus of PTHrP. Here, we show that
indeed, these domains of PTHrP are essential for
development and survival, strengthening the hypothe-
sis that many of the actions attributed to the N terminus
of PTHrP are mediated by regions within PTHrP-(67–
137), but also that these functions are paracrine, auto-
crine, and intracrine in nature. This is further sup-
ported by the fact that daily injections of PTHrP failed
to rescue the lethal phenotype of Pthrp/ mice.
Although PTH-(1–34) and PTHrP-(1–36) are equi-
potent through the PTH1R in rodents (34), it remains
unclear whether the absence of the NLS or C terminus
impairs the N-terminal interaction with this or other
Figure 4. Ablation of PTHrP-(67–137) alters gene expres-
sion. A) mRNA expression of genes involved in osteogen-
esis, chondrogenesis, apoptosis, and hematopoiesis (2-d-
old mice; n6) revealed dysregulation, with several genes
underexpressed (Runx2, Ocn, Sox9, Crtl1, -catenin, Bcl2,
Runx1, Gata1, PU.1) and overexpressed (Fgf3, Ihh) in the
/ tibia compared to controls (/; /). No differ-
ence in Pthrp, or PTH1R and PPAR mRNA expression was
found (not shown). Similar expression patterns were
found in the calvaria (Supplemental Fig. S3). B) Western
blot analysis of tibial and bone marrow protein extracts
revealed lesser amounts of RUNX2, SOX9, RUNX1, EPHRIN
B2 (EPB2), -CATENIN (-CAT), Rb, PAX5, NOTCH1, and
GATA1, and increased levels of GSK-3, P21, and P16/Ink4a.
Values are means 
 sd. *P  0.05.
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receptors. While speculative, this could be accepted as
a potential explanation for the abnormal phenotype of
Pthrp/ mice, which may represent a hypomorphic
form of the Pthrp/ phenotype (7). However, we
believe that these effects are independent of the N
terminus, mediated at the intracrine level by the NLS
and at the autocrine and paracrine level by cell mem-
brane receptors for the C terminus of PTHrP. Cell
culture studies have shown that the NLS of PTHrP
associates with importin  and GTP-Ran to promote its
translocation into the nucleus (16, 17), where it inter-
acts with RNA (14, 19) to reduce apoptosis (15).
Likewise, other investigators have shown that the mi-
dregion and C terminus of PTHrP interact with cell
surface receptors to increase intracellular cAMP and
calcium concentrations (35–37); however, the structure
of these receptors remains unknown. One might spec-
ulate that the increased osteoclast number in the
trabeculae of Pthrp/ mice could have resulted from the
absence of PTHrP-(107–111), also known as osteosta-
tin, which inhibits osteoclastic activity (33), while the
decreased proliferation and increased apoptosis could
also been a consequence of C-terminal and midregion
deletion, both of which have been shown to promote
cell proliferation (18, 37, 38).
Pthrp/ mice have a similar gross appearance to the
Pthrp/ mice (7); however, Pthrp/ pups die within
minutes of birth with evidence of cyanosis and respira-
tory failure (7), while Pthrp/ pups appear normal at
birth, with most of them dying after d 3. Since Pth1r/
fetuses die earlier in development than Pthrp/ fetuses
(7, 39); this indicates that the ontogenic functions of
the N terminus of PTHrP occur earlier in development
and further substantiates our findings that PTHrP has
functions not mediated by this receptor. Of interest,
mice lacking the cartilage linking protein 1 (Crtl1/;
Hapln1/) (40) had a similar phenotype to Pthrp/
and Pthrp/ pups, including abnormal craniofacial
development, chondrodysplasia and dwarfism. How-
ever, unlike Pthrp/ mutants, but similar to Pthrp/
pups, Crtl1/ die at birth from respiratory failure (7,
40). The decreased mRNA expression of Crtl1 and its
regulator, Sox9, suggests direct and indirect interac-
tions between PTHrP and CRTL1 (HAPLN1) (41). We
also believe that P63 and P16/Ink4a, which were dereg-
ulated, are central to the Pthrp/ phenotype. P63 is a
p53-related protein that regulates morphogenesis and
senescence, and P63/ mice have aberrant skeletogen-
esis, hyperkeratosis, and short life span (42, 43).
Skeletal mineralization was reduced in Pthrp/ mice,
which is in contrast with the increased and premature
ossification observed in Pthrp/ mice (7), indicating
that PTHrP-(67–137) regulates skeletal development
differently than the N terminus. It also shows that
PTHrP-(67–137) has essential roles in the commitment
of stromal cells to the skeletogenic lineage, as docu-
mented by the underexpression of Runx2, Ocn, Sox9,
EphrinB2, -catenin, and Crtl1, and overexpression of
Fgf3, Ihh, and GSK-3. Sox9 and Runx2 are the master
transcription factors for chondrogenesis and osteogen-
esis, respectively. The overexpression of Ihh, Fgf3, and
GSK-3 in Pthrp/ mice supports PTHrP as an inhibitor
of these factors, but also that this inhibition is indepen-
dent of PTH1R signaling (44). We believe that en-
hanced Fgf3 expression contributed in part to abnormal
skeletal morphogenesis ofPthrp/mice as fibroblast growth
factor (FGF) 3 is a negative regulator of chondrocyte
proliferation and bone growth, gain-of-function muta-
tions of the FGF receptors are responsible for most
forms of human chondrodysplasias (44), and mice
overexpressing FGFR3 have skeletal phenotypical simi-
larities to that of Pthrp/ mice (45, 46). On the basis of
these findings, we propose that a lack of stromal cell
commitment is central to the skeletal phenotype ob-
Figure 5. Model for the role of PTHrP-(67–137)
in skeletogenesis and hematopoiesis. A) The work
presented here indicates that PTHrP-(67–137)
increases Runx2 mRNA expression to lead mesen-
chymal stem cells to the osteogenic and chondro-
genic lineages. By inducing Sox9 mRNA expres-
sion in the epiphyses and metaphyses, PTHrP
commits stem cells to chondrogenesis, while in
the diaphysis, PTHrP-driven mRNA expression of
Runx2 commits stem cells to osteogenesis. PTHrP-
(67–137) also regulates other important skeleto-
genic genes (-catenin, Ihh, Fgf3, Crtl1, ephrin B2)
(Fig. 4A). B) Underexpression of Runx1 and
Notch1, which are required for hematopoiesis, and
underexpression of PU.1, Pax5, and Gata1, which
are necessary for further hematopoietic differen-
tiation, links PTHrP to functions not previously
described. It also suggests that PTHrP participates
in the communication between the bone/bone
marrow compartments. C) Dysregulation of genes
involved in apoptosis and aging (GSK-3, P16/Ink4a,
P21, -catenin, P63, Bcl-2) supports PTHrP as a
regulator of these processes. HSC, hematopoietic
stem cell; LMP, lymphoid-myeloid progenitor;
GMP, granulocyte-monocyte progenitor; CLP, com-
mon lymphoid progenitor; MEP, megakaryocyte-
erythroid progenitor; Meg, megakaryocyte.
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served in Pthrp/ mice, as osteoblast and chondrocyte
number was decreased in skeletal tissue. The low chon-
drocyte number and disorganization in Pthrp/ mice
demonstrates that the paracrine effects of PTHrP are
dependent on post-transcriptional modifications of
PTHrP, expression of distinct PTHrP receptors, or
intracrine functions, reinforcing the theory of alterna-
tive PTH1R ligands, and/or PTHrP signaling pathways
(36, 47). The fact that mice expressing PTHrP-(1–84)
(26) show less severe skeletal abnormalities than
Pthrp/ mice, with apparently normal hematopoiesis
supports distinct functions for the midregion of
PTHrP.
The discovery that Pthrp/ mice had defective hema-
topoiesis raises important questions on the role of
PTHrP in the communication between osteogenic and
hematopoietic precursors, regulation of bone mass,
and hematopoiesis. Since constitutive expression of the
PTH1R in murine osteogenic cells delays hematopoie-
sis (48), this implies that there are complementary
actions among the different domains of PTHrP, and
likely PTH, within the bone and bone marrow compart-
ments. It remains to be elucidated whether the effects
of PTHrP-(67–137) on osteoblasts and hematopoietic
cells are direct or the result of intercellular communi-
cations in the bone microenvironment.
It is unclear why Pthrp/ pups failed to thrive, but it
could relate to an inability to nurse from craniofacial
malformation, dental malocclusion, tongue protrusion,
as well as dysregulated energy metabolism. Endocrine
dysregulation is possible as enteral feeding did not
rescue Pthrp/ mice, which also had low insulin con-
centrations. It has been reported that PTHrP regulates
insulin secretion by pancreatic  cells (22, 30). The fact
that the nipples from Pthrp/ pups lacked the typical
epidermal invaginations, but had a rudimentary mam-
mary duct system, suggests that PTHrP-(67–137) is not
required for mammary mesenchyme formation. PTHrP
is an important mediator of epithelial–mesenchymal
interactions since humans and mice lacking PTHrP or
the PTH1R have a failure of embryonic mammary
gland development due to a defect in mammary mes-
enchyme differentiation (9, 10). These effects might
be, in part, mediated by P63 as inactivating mutations
of P63 in humans are associated with mammary gland
aplasia (49).
In summary, the midregion, NLS, and C terminus of
PTHrP are essential for survival. The presence of
skeletal, hematopoietic, and lethal phenotypes in
Pthrp/ mice supports the hypothesis that PTHrP is
pleiotropic, and its biological actions are mediated by
receptors other than the PTH1R. It also indicates that
the specificity of PTHrP to various targets results from
tissue-specific modifications leading to autocrine, para-
crine, and intracrine functions.
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